FindTrial
Sign In

A phase II study of Amrubicin in patients with previously treated small cell lung cancer

A phase II study of Amrubicin in patients with previously treated small cell lung cancer - A phase II study of Amrubicin in patients with previously treated small cell lung cancer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000141
Enrollment
30
Registered
2005-09-08
Start date
2005-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

Amrubicin 40 mg/m2 on days 1, repeated every 21 days.

Sponsors

Kinki University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically or cytologically confirmed SCLC Stage IIIB/IV Prior one or two regimens Measurable disease ECOG PS 0-1 Adequate organ function Age 20-74 Written informed consent

Exclusion criteria

Exclusion criteria: Pregnancy or breast feeding Past history of drug hypersensitivity SVC syndrome Pleural or pericardial effusion that required drainage Active infection Interstitial pneumonia or active lung fibrosis Symptomatic brain metastasis Active concomitant malignancy Uncontrolled diabetes Uncontrolled heart disease

Design outcomes

Primary

MeasureTime frame
response rate—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026